BrainsWay Ltd. (BWAY) AI Stock Analysis

BrainsWay Ltd. develops and markets noninvasive neurostimulation treatments for mental health disorders across the United States, Europe, Israel, and internationally. Its core platform, Deep Transcranial Magnetic Stimulation (Deep TMS), is designed to treat major depressive disorders, anxious depression, obsessive-compulsive disorders, and smoking addiction. BrainsWay also addresses conditions including bipolar disorders, post-traumatic stress disorders, schizophrenia, Alzheimer's disease, autism, chronic pain, multiple sclerosis, post-stroke rehabilitation, and Parkinson's disease. Headquartered in Jerusalem, Israel, the company primarily serves doctors, hospitals, and medical centers specializing in psychiatry.

BrainsWay grew annual revenue from $29.7M in FY2021 to $52.2M in FY2025, delivering an 18.8% five-year revenue CAGR. After posting net losses of -$6.5M in FY2021, -$13.3M in FY2022, and -$4.2M in FY2023, the business turned profitable with net income of $2.9M in FY2024 and $7.6M in FY2025. Gross margin reached 75.4% in FY2025, while operating margin expanded to 8.3%. In the trailing twelve months ended June 30, 2026, revenue stood at $60.7M with EPS of $0.23, supported by quarterly revenue growth of 35.4% and quarterly earnings growth of 59.8%.

As of June 30, 2026, BrainsWay held $62.4M in cash and short-term investments against $7.1M in total debt, resulting in net cash of $55.2M. The company maintains liquidity with a current ratio of 3.59 and a debt-to-equity ratio of 0.09. In FY2025, operating cash flow reached $18.2M and free cash flow stood at $16.4M after capital expenditures of $1.8M. Over the past five years, the company reduced its share count by 39.0%.

At a share price of $11.44 and a market capitalization of $460.5M, BrainsWay trades at a trailing P/E of 49.7x, compared to 24.6x for the median of its US-listed Healthcare peers. Its forward P/E is 17.9x versus the peer median of 17.3x, while its enterprise value to EBITDA ratio is 41.8x compared to the peer median of 12.0x. Over the past year, BWAY gained 43.0%, outperforming the 16.8% return of the S&P 500 (SPY). Over five years, the stock returned 193.0% against 83.0% for the benchmark index.

Wall Street coverage includes 3 Strong Buy recommendations, with no Buy, Hold, Sell, or Strong Sell ratings. The mean price target is $19.27, representing a 68.4% premium over the last close of $11.44. For the current fiscal year ending December 31, 2026, consensus estimates project revenue of $69.2M and EPS of $0.31, representing 70.4% EPS growth. For next fiscal year, 3 analysts project revenue of $85.3M and EPS of $0.51. BrainsWay beat EPS estimates in 3 of the last 4 quarters, and its next earnings date is November 10, 2026.

This page is an AI-written research summary of BrainsWay Ltd. (BWAY). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: BWAY income statement, BWAY balance sheet, BWAY key metrics, BWAY analyst forecast, BWAY chart. See the BWAY stock overview for the latest quote and news.